Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells
UMass Chan Affiliations
Department of Medicine, Division of Hematology/OncologyDocument Type
Journal ArticlePublication Date
2013-03-13Keywords
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveStem Cells
Cancer Biology
Cell Biology
Hematology
Hemic and Lymphatic Diseases
Oncology
Metadata
Show full item recordAbstract
Studies on chronic myeloid leukemia (CML) have served as a paradigm for cancer research and therapy. These studies involve the identification of the first cancer-associated chromosomal abnormality and the subsequent development of tyrosine kinase inhibitors (TKIs) that inhibit BCR-ABL kinase activity in CML. It becomes clear that leukemia stem cells (LSCs) in CML which are resistant to TKIs, and eradication of LSCs appears to be extremely difficult. Therefore, one of the major issues in current CML biology is to understand the biology of LSCs and to investigate why LSCs are insensitive to TKI monotherapy for developing curative therapeutic strategies. Studies from our group and others have revealed that CML LSCs form a hierarchy similar to that seen in normal hematopoiesis, in which a rare stem cell population with limitless self-renewal potential gives rise to progenies that lack such potential. LSCs also possess biological features that are different from those of normal hematopoietic stem cells (HSCs) and are critical for their malignant characteristics. In this review, we summarize the latest progress in CML field, and attempt to understand the molecular mechanisms of survival regulation of LSCs.Source
Protein Cell. 2013 Mar;4(3):186-96. doi: 10.1007/s13238-013-2115-0. Link to article on publisher's siteDOI
10.1007/s13238-013-2115-0Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29517PubMed ID
23483480Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1007/s13238-013-2115-0